Cervical cancer burden in Latin America and the Caribbean: Where are we?

Pilleron, Sophie; Cabasag, Citadel J.; Ferlay, Jacques; Bray, Freddie; Luciani, Silvana; Almonte, Maribel; Piñeros, Marion

doi:10.1002/ijc.32956

Cited by 58 publications

(66 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cervical cancer screening programs hastened the declines upon their implementation in many countries in Europe, Oceania, and Northern America, despite the observations of increasing risk among younger generations of women in some of these countries 170,171 and also in Japan, 172 which may in part reflect changing sexual behavior and increased transmission of HPV that is insufficiently compensated by cytologic screening 173,174 . Rates have also decreased in countries in the Caribbean and Central and South America (eg, Argentina, Chile, Costa Rica, Brazil, and Colombia) during the 2000s, although incidence rates remain high 175 . In the absence of effective screening, as in Eastern Europe and Central Asia, there have been rapid increases in premature cervical cancer mortality in recent generations 176 .…”

Section: Resultsmentioning

confidence: 99%

“…173,174 Rates have also decreased in countries in the Caribbean and Central and South America (eg, Argentina, Chile, Costa Rica, Brazil, and Colombia) during the 2000s, although incidence rates remain high. 175 In the absence of effective screening, as in Eastern Europe and Central Asia, there have been rapid increases in premature cervical cancer mortality in recent generations. 176 Perhaps most concerning are the uniform rises recently age-standardized rate among men, and the highest national rates among men and women are superimposed.…”

Section: Cervical Cancermentioning

confidence: 99%

See 1 more Smart Citation

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Sung

Ferlay

Siegel

et al. 2021

CA A Cancer J Clinicians

Self Cite

69,625

167

46,994

View full text Add to dashboard Cite

This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2‐fold to 3‐fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2‐fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Cervical Cancermentioning

confidence: 99%

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Sung

Ferlay

Siegel

et al. 2021

CA A Cancer J Clinicians

Self Cite

69,625

167

46,994

View full text Add to dashboard Cite

show abstract

“…In low-income countries, health systems are usually developing, whereas, in middle-income countries (MIC), a better health framework makes it possible to design and implement more sophisticated programs. Unfortunately, population-based cost-effectiveness studies are scarce in MIC, limiting the incorporation of new technologies [ 3 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country

et al. 2021

View full text Add to dashboard Cite

Objective To report a modelling study using local health care costs and epidemiological inputs from a population-based program to access the cost-effectiveness of adopting hrHPV test. Methods A cost-effectiveness analysis based on a microsimulation dynamic Markov model. Data and costs were based on data from the local setting and literature review. The setting was Indaiatuba, Brazil, that has adopted the hrHPV test in place of cytology since 2017. After calibrating the model, one million women were simulated in hypothetical cohorts. Three strategies were tested: cytology to women aged 25 to 64 every three years; hrHPV test to women 25–64 every five years; cytology to women 25–29 years every three years and hrHPV test to women 30–64 every five years (hybrid strategy). Outcomes were Quality-adjusted life-years (QALY) and Incremental Cost-Effectiveness Ratio (ICER). Results The hrHPV testing and the hybrid strategy were the dominant strategies. Costs were lower and provided a more effective option at a negative incremental ratio of US$ 37.87 for the hybrid strategy, and negative US$ 6.16 for the HPV strategy per QALY gained. Reduction on treatment costs would influence a decrease in ICER, and an increase in the costs of the hrHPV test would increase ICER. Conclusions Using population-based data, the switch from cytology to hrHPV testing in the cervical cancer screening program of Indaiatuba is less costly and cost-effective than the old cytology program.

show abstract

“…Cervical cancer ranks globally as the fourth most common malignancy in women with over 570,000 new cases and 311,000 deaths annually [1,2]. This follows breast, colorectal and lung cancer [1].…”

Section: Introductionmentioning

confidence: 99%

Cervical Cancer Prevention: Unearthing the Unspoken Barriers for Caribbean Women

Hem-Lee-Forsyth

2021

JGWH

View full text Add to dashboard Cite

show abstract

Cervical cancer burden in Latin America and the Caribbean: Where are we?

Cited by 58 publications

References 31 publications

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country

Cervical Cancer Prevention: Unearthing the Unspoken Barriers for Caribbean Women

Contact Info

Product

Resources

About